|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
PHAGOCYTES
From the Department of Medicine, University of
California at Los Angeles (UCLA) School of Medicine, Los Angeles, CA.
The host defense roles of neutrophil elastase in a porcine
skin wound chamber model were explored. Analysis of wound fluid by
acid-urea polyacrylamide gel electrophoresis, Western blot, and
bacterial overlay confirmed that the neutrophil-derived protegrins constituted the major stable antimicrobial polypeptide in the wound
fluid. The application to the wound of 0.10 and 0.25 mM N-methoxysuccinyl-alanine-alanine-proline-valine (AAPV) chloromethyl ketone, a specific neutrophil elastase inhibitor (NEI), blocked the
proteolytic activation of protegrins and diminished the associated antimicrobial activity as detected by radial diffusion assay against Staphylococcus epidermidis, Staphylococcus
aureus, Escherichia coli, Pseudomonas
aeruginosa, and Candida albicans or by bacterial gel
overlay against S epidermidis and E
coli. The application of the related cathepsin G
inhibitor (CGI),
benzyloxycarbonyl-glycine-leucine-phenylalanine (ZGLF) chloromethyl
ketone, had no effect. In wound chambers that received
106 colony-forming unit (CFU)/mL of S
epidermidis, the presence of NEI significantly decreased the
24-hour clearance of bacteria from the wound compared to wounds treated
with CGI or solvent only. Neither inhibitor, at 0.10 or 0.25 mM
concentration, affected leukocyte accumulation or degranulation in the
wound chambers. The in vitro microbicidal decrement due to NEI was
restored by an amount of the specific protegrin (PG-1), which was
equivalent to the measured difference of protegrin between control and
inhibited chambers. Administration of 1 µg/mL exogenous PG-1 4 hours
after chamber preparation was sufficient to normalize in vivo
antimicrobial activity. Although pharmacologic NEIs are promising
candidates as anti-inflammatory drugs, they may impair host defense in
part by inhibiting the activation of cathelicidins by neutrophil elastase.
(Blood. 2001;97:297-304) Neutrophil elastase is an abundant serine protease
of mammalian granulocytes,1 where it is concentrated in
the granules that are mainly destined to fuse to
phagosomes.2 There is abundant evidence that elastase can
contribute to inflammatory tissue injury,3-5 and various
natural and synthetic inhibitors of elastase are under development as
pharmaceuticals to diminish tissue damage in inflammatory diseases.6 In contrast, knowledge about functions of
neutrophil elastase in host defense is very limited. Patients with
Chediak-Higashi syndrome lack neutrophil elastase in mature
neutrophils and suffer from recurrent bacterial infections, but other
abnormalities coexisting in this disease obscure a possible causal
relationship.7 Mice made homozygous for a disrupted
neutrophil elastase gene have diminished resistance to Klebsiella
pneumoniae and Escherichia coli sepsis.8
Although one possible target for elastase is a bacterial outer-membrane
protein OmpA,9 it is not clear how the lack of neutrophil
elastase causes the host defense defect. In contrast, mice that were
made deficient in the neutrophil protease cathepsin G were
phenotypically normal when challenged with Staphylococcus aureus, K pneumoniae and E
coli.10
Neutrophil elastase has modest direct antimicrobial
effects11 that are most apparent in low-ionic-strength
media, and these could synergize with other antimicrobial proteins of
phagocytic granules. Alternatively, elastase may act indirectly by
proteolytic activation of other antimicrobial systems. Importantly, the
precursors of cathelicidins, abundant antimicrobial peptides of
mammalian neutrophils, are activated by catalytic amounts of neutrophil elastase but not by other related proteases.12-16 Although
the neutrophils of many if not all mammalian species contain
cathelicidins, porcine neutrophils are unusually well endowed with
these peptides, including protegrins, PR-39, prophenins, and porcine
myeloid antimicrobial peptides (PMAPs)17-24; however,
porcine neutrophils have not been reported to contain any peptides of
the defensin family, peptides that are abundant in human neutrophils.
Porcine neutrophils are the sole known sources of protegrins, potently
and broadly microbicidal peptides of 16-18 residues.18 We
previously showed that porcine neutrophils, when stimulated with
phorbol myristate acetate (PMA) or latex beads, generated extracellular
microbicidal activity against Listeria monocytogenes or
E coli by elastase-mediated activation of secreted
proprotegrins,16 and we noted that the activity of
protegrins was a major contributor to the antibacterial activity of
neutrophil secretions. We hypothesized that inhibition of neutrophil
elastase would block the activation of antimicrobial cathelicidins and
impair local antimicrobial defenses. In the present study, using a
porcine skin wound model and the local application of a specific
inhibitor for neutrophil elastase, we explored the effects of the
inhibitor on antimicrobial properties of wound fluid in vivo.
Reagents
Microbes and culture conditions
Porcine skin wound fluid generation All animal procedures were approved by the UCLA Chancellor's Animal Research Committee. Porcine skin wound model was created as described earlier with slight modifications.27 Female Yorkshire pigs (40-60 pounds) used in the experiments were fed a Minipig porcine diet (LabDiet 5P94, ProLab, Brentwood, MO). Wounds were generated under general anesthesia with 10 mg/kg tiletamine (Telazol; Fort Dodge, Cherry Hill, NJ) and 2 mg/kg xylazine (AnaSed; Lloyd Laboratories, Shenandoah, IA). The skin was surgically sanitized with 7.5% povidone iodine scrub followed by 70% isopropanol. Medium partial-thickness excisional wounds (2-cm wide,2 1- to 1.5-mm deep) were created with a scalpel in duplicate or quadruplicate in the regions immediately caudal to the inferior angle of the scapula. Polyvinyl chambers (P.A. Medical Inc, Columbia, TN) were attached and secured by tape over each wound. Each chamber received 2 mL sterile HBSS without phenol red and with or without protease inhibitors (0.1, 0.25, 0.5, 1, or 2 mM) or their solvent. Bacteria or fungi at 1 × 106 CFU/mL final concentration was also included in some chambers. Wound fluids in the chambers were removed by aspiration at 4, 24, or 48 hours.Analysis of porcine wound fluid Total and differential leukocyte counts were performed for each chamber (Diff-Quik; Dade Behring, Newark, DE). To quantify microbes, the fluid was separated into cell-free supernatant and cell pellet by centrifugation at 210g for 3 minutes. In some experiments, the cell pellet was lysed by 3 10-second bursts of sonication in HBSS. For either cell-free supernatant or cell lysate, microbial CFUs were determined by spreading on antibiotic-free TSA plates. In a preliminary set of experiments, microbial CFUs were determined in wound fluid before and after the cells and debris were removed by centrifugation at 210g for 3 minutes. The CFUs did not differ significantly (data not shown). Therefore, subsequent antibacterial activity assays and biochemical analyses of wound fluids were performed on the cell-free supernatant.Neutrophil elastase and cathepsin G inhibition assays In a modification of a previously described procedure,28 2 times the concentrations of NEI (312 nM to 80 µM) and HNE (625 nM to 5 µM) or CGI (63 nM to 8 µM) and human cathepsin G (125 nM to 1 µM) were reconstituted in 1 × phosphate-buffered saline (PBS). NEI with elastase or CGI with cathepsin G (5 µL each) were admixed in a checkerboard fashion in a 96-well microtiter plate (Falcon flexible U-bottom; Becton-Dickinson Labware, Franklin Lakes, NJ) and incubated in a humidified chamber for 1 hour at 37°C. We added 75 µL of a neutrophil elastase-specific chromogenic substrate, which comprises 0.8 mM methoxysuccinyl-AAPV-P-nitroanalide in 0.1 M Tris-HCl (tris[hydroxymethyl] aminomethane-hydrochloride)/0.15 M sodium chloride (NaCl) (pH 7.5), or cathepsin G-specific chromogenic substrate, which comprises 3 mM succinyl-AAPF-P-nitroanalide in 0.1 M Tris-HCl (pH 7.5). After 20 minutes of elastase or 1.5 hours of cathepsin G incubation at 37°C, the reaction was stopped with 40 µL of 50 µM soybean trypsin inhibitor in 0.1 M Tris-HCl/0.15 M NaCl (pH 7.5). Absorbance was read at 405 nm in a variable wavelength spectrophotometer (SpectraMAX 250 Kinetic Microplate Spectrophotometer; Molecular Devices, Sunnyvale, CA).Colony-forming unit assay A CFU assay was performed to determine the viable bacterial or fungal concentration in porcine skin wound fluids. Briefly, 25-100 µL wound fluid was diluted in HBSS, and aliquots were plated on TSA plates. After incubation for 18 hours at 37°C, the colonies were counted, and the CFU/mL concentrations were calculated.Radial diffusion assays Radial diffusion assays (RDAs) were performed as described previously.29 Briefly, the underlay consisted of 1% agarose and 1:100 dilution TSB in 10 mM sodium phosphate (NaP), a low-ionic buffer (pH 7.4), or in 10 mM NaP with 100 mM NaCl, a higher-ionic buffer (pH 7.4). Overlay consisted of 6% TSB and 1% agarose in PBS for all assays. We mixed 4 × 106 bacteria or fungi with 10 mL gel-underlay solutions kept molten at 48°C and poured into 100 cm2 square petri dishes. A series of 3.2-mm diameter wells were punched after the agarose solidified, and 5 µL wound fluids or standard PG-1 or PG-3 solution was added into designated wells. Plates were incubated at 37°C for 3 hours to allow for peptide diffusion. The microbe-laden underlay was then covered with 10 mL molten overlay, and the plates were allowed to harden. Antimicrobial activity was identified as a clear zone around the well, which was absent of microbial growth after 18 hours incubation at 37°C. The activity was represented in radial diffusion units (RDUs) defined as: [diameter of clear zone in mm 3.2 mm] × 10. Assays were performed in duplicate and repeated at
least once.
Gel-overlay assay The gel-overlay assay was performed as described previously.29 Briefly, proteins and peptides from 100 µL wound fluid were concentrated using 10 µL Strataclean resin (Stratagene) and separated by acid-urea polyacrylamide gel electrophoresis (AU-PAGE). The gel was washed 20 minutes in 10 mM NaP, then it was placed on a premade 1% agarose plate containing 10 mM NaP with 100 mM NaCl (pH 7.4), 1:100 dilution TSB, 1% porcine serum, and 4 × 106 L monocytogenes or E coli. The plate was then incubated at 37°C for 3 hours to allow the proteins and peptides in the polyacrylamide gel to diffuse into the underlying bacterial layer. The polyacrylamide gel was then removed, and the bacterial layer was overlaid with a nutrient layer that contained 6% TSB in 1% agarose. Clear zones without bacterial growth represented antibacterial activity. Duplicate AU-gels were electrophoresed and Coomassie-stained to correlate antibacterial activity with protein bands.Western blot analysis For Western blot analysis, after AU-PAGE, proteins were electroblotted to Immobilon-P PVDF membranes (Millipore, Bedford, MA) in 0.7% acetic acid. The blots were probed with 1:1000 dilution of monoclonal antibody (mAb) anti-PG (recognizes PG-1 and PG-3) and a 1:1000 dilution of rabbit antimouse immunoglobulin G (IgG) alkaline-phosphatase conjugate, and then they were developed in 5-bromo-4-chloro-3-indolylphosphate-nitroblue tetrazolium solution. Synthetic PG-1 and PG-3 were used as protegrin standards.Lysoplate assay for muramidase activity of lysozyme Briefly, a mixture of 0.5 mg/mL lyophilized Micrococcus lysodeiktikus (M luteus) and 1% low EEO agarose in 66 mM NaP buffer [pH 7.0] was kept at 45°C and poured in a level sterile dish.30 Evenly spaced 3-mm wells were punched in the solidified agar, and a 5-µL test sample was introduced into each well. Lysozyme enzymatic activity was determined by measuring the zone-of-clearance diameters after an 18-hour incubation at room temperature.The effect of NEI on superoxide anion production by porcine neutrophils Porcine neutrophil isolation and superoxide anion (· O2 ) production assay were performed
as described earlier.31 Briefly, to isolate porcine
neutrophils, 30 mL ethylenediamine tetraacetic acid (EDTA)-treated
blood (final concentration, 5 mM EDTA) was mixed with 30 mL 3% dextran
in PBS and was incubated for 30 minutes at room temperature. The
supernatant was carefully removed from the dextran-sedimented blood,
overlaid on 10 mL Histopaque 1.077 (Sigma), and centrifuged at 300g for
25 minutes at room temperature. Neutrophils were collected from the
bottom of the tube, and contaminating red blood cells were lysed with
10 mL 0.2% NaCl for 30 seconds. Isotonicity was restored with 10 mL
1.6% NaCl. Neutrophils (more than 95% of the cells) were washed once
in ice-cold PBS solution without divalent cations and kept on ice.
The superoxide anion (· O2 Statistical analysis Unless otherwise stated, assays were performed in at least triplicate for each independent experiment. Where applicable, results from duplicate chambers were averaged for each pig tested. Sets of independent experiments were compared with a paired t test when analyzing individual experiments of inhibitor-treated wound fluids against solvent-treated fluids (SigmaStat; SPSS Inc, Chicago, IL). Error bars represent the SEM.
Protegrins are the principal antibacterial substances in porcine wound fluid Because in previous studies we identified protegrins as the principal stable antimicrobial substances secreted by porcine neutrophils,16 the antibacterial potency of wound fluid was determined relative to the activity of synthetic protegrins. To identify the antimicrobial components, the composition and activity of wound fluid generated from chambers injected with HBSS and solvent only (n = 4) was evaluated using AU-PAGE, gel-overlay antibacterial assay, and Western blot with a mAb to protegrins. Wound fluid was extracted and subjected to AU-PAGE, in which proteins and peptides were separated based on their positive-charge density. Distinct bands near the dye front of the AU-gel were identified as protegrins: They migrated similarly to the synthetic PG-1 (Figure 1A, lane S), reacted in a Western blot with mAb anti-PG (Figure 1B, lane S), and were shown to have antibacterial activity in a gel-overlay assay against E coli (Figure 1C, lane S) and S epidermidis (not shown). As judged by the overlay assay, protegrins were the predominant antibacterial components in porcine skin wound fluid. Moreover, under these conditions (10 mM NaP/100 mM NaCl) there was no evidence of direct antimicrobial activity of neutrophil elastase.
Elastase inhibition blocks the activation of proprotegrin in vivo We showed previously that protegrins are stored in porcine neutrophils as inactive proprotegrins and that neutrophil elastase is required for in vitro activation of protegrins.15,16 To investigate if elastase was the converting enzyme that was responsible for the activation of protegrins in vivo, we employed NEI or CGI, specific inhibitors for either neutrophil elastase or cathepsin G, respectively, both of which are abundant serine proteases from neutrophil granules. The CGI also served as a control for the potential effect of the chloromethyl ketone moiety on the antibacterial and biochemical properties of porcine skin wound and as a control for the reported antichemotactic effects of inhibitors of neutrophil elastase and cathepsin G.32 As shown in Figure 1A (AU-PAGE) and Figure 1B (Western blot), protegrins were generated in saline-induced wound fluid (HBSS with solvent, lane S). The wound fluid was induced in the presence of CGI, but the characteristic protegrin bands were not detected in the wound fluid that was induced in the presence of NEI. In the gel-overlay assay (Figure 1C), protegrins were the predominant antibacterial components in the normal wound fluid and the CGI-treated wound fluid. However, if NEI was present during wound fluid production, the antibacterial activity corresponding to the protegrin bands was severely reduced. Two bactericidal bands not usually seen in wound fluid and migrating much more slowly were present in the upper part of the AU-gel. To examine these additional bands further we used 1 µg pPG-3 in the Western analysis and identified one band in the wound fluid (Figure 1B, arrow) that comigrated with pPG-3 and was reactive with mAb anti-PG.In vitro inhibition of neutrophil elastase by NEI and cathepsin G by CGI To determine the inhibitory capacity of the specific NEI, 0.312-2.5 µM 8.7-70 µg/mL HNE was coincubated with 0.16-40 µM NEI and subjected to a chromogenic assay of residual elastase activity (data not shown). NEI inhibited the activity of HNE in a
stoichiometric ratio of 1. In a similar set of experiments, 0.063-0.5 µM 1.7-13.5 µg/mL human cathepsin G was inhibited by an
equimolar ratio of its specific inhibitor, CGI (data not shown).
At moderate concentrations, NEI or CGI have no effect on superoxide production, neutrophil influx, and degranulation In experiments with neutrophils from 3 pigs, superoxide was measured by the cytochrome c/SOD assay during a 20-minute incubation of 1 × 106 neutrophils with 1 × 107 opsonized E coli with or without the addition of 1 mM NEI or CGI. There were no differences in superoxide production in a pair-wise comparison between solvent and NEI- or CGI-treated wound fluid (P > .39; data not shown) (n = 3). This confirmed the previously reported lack of effect of the cell-impermeable protease inhibitors, NEI and CGI, on the production of superoxide.33White blood cells (WBCs) were quantitated for each chamber to determine
if the inhibitors influenced the influx of WBCs into the wounds. Figure
2 indicates that at NEI concentrations of
0.1 and 0.25 mM, the ratio of WBCs in the solvent-treated to
NEI-treated chambers was 1, demonstrating no difference in the cell
numbers between the control and inhibited chambers
(P > .5). The WBC counts in 0.25 mM CGI-treated chambers
were also unchanged from the solvent-only control fluid (data not
shown). However, as compared with the solvent control, increasing the
NEI concentration to 0.5-2.0 mM reduced the number of WBCs recovered
from the NEI-inhibited chambers by 2- to 4-fold. Regardless of NEI
concentration, the control chambers contained 94.6% ± 0.6% WBCs as
neutrophils (n = 29), and inhibitor chambers (both NEI and CGI)
contained an equivalent percentage (94.0% ± 0.6%) (n = 29).
Subsequent experiments were performed using either 0.10 or 0.25 mM NEI
to obviate antichemotactic effects.
To measure the effect of the protease inhibitors on degranulation, the enzymatic activity of lysozyme, which is stored in both the azurophil and specific granules of the neutrophil,34 was measured in solvent-only control and NEI- and CGI-inhibited wound fluids using a lysoplate assay: solvent only, 1.05 ± 0.07 µg/mL (n = 13); NEI, 1.01 ± 0.08 µg/mL (n = 10); CGI, 0.94 ± 0.09 µg/mL (n = 3). No significant difference in lysozyme activity was measured in a pair-wise comparison between the wound fluids (P > .5). Elastase inhibition impairs the in vivo clearance of bacteria from wound fluid We observed that the common spontaneous infections of the wound fluid with porcine skin-derived coagulase-negative S epidermidis resulted in 100-times more bacteria in NEI-treated wound fluid than in CGI-treated wound fluid (data not shown). To examine the effects of protease inhibitors on the resistance of the skin wound to a defined bacterial inoculum, we introduced 1-2 × 106 CFU/mL porcine-derived S epidermidis into the wound with or without NEI or CGI and examined the fate of the bacteria 4 and 24 hours later. In Figure 3, the effect of inhibitors on antimicrobial activity was expressed as "fold-inhibition of killing," defined as the ratio of CFU counts in the control and inhibitor-treated chambers. At 4 hours, there were no significant differences in CFU counts between saline (solvent only) control and inhibitor-treated chambers (not shown). At 24 hours, there was an approximate 115-fold and 70-fold reduction in microbicidal activity in wound fluids treated with 0.10 mM and 0.25 mM NEI, respectively, compared with solvent-treated control wound fluids (P < .001). NEI-treated wound chambers exposed to E coli, C albicans, or P aeruginosa behaved similarly (data not shown). Wound fluids treated with 0.25 mM CGI showed no difference in bacterial CFUs compared with control (Figure 3, right panel; P > .5). Although the chambers treated with 0.10 mM NEI showed more variation in antimicrobial activity than those treated with 0.25 mM NEI, the in vivo antimicrobial activities of these 2 concentrations of NEI were not significantly different from each other (P > .2). NEI at a concentration of 0.25 mM was thus used in the remaining experiments.
Inhibiting neutrophil elastase decreases the ex vivo antimicrobial activity of wound fluid Wound fluid collected from each chamber at 24 hours was subjected to a radial diffusion assay to measure ex vivo antimicrobial activity. The antibacterial activity of the wound fluid was determined by an RDA with our laboratory test strains of S epidermidis, S aureus, P aeruginosa, E coli, and C albicans in either low-ionic (10 mM NaP) or higher-ionic (10 mM NaP/100 mM NaCl) buffer conditions (Figure 4). The antimicrobial activity of fluid formed in chambers without added microbes or inhibitor was similar to fluid from chambers containing bacteria and solvent (control). However, the in vitro antimicrobial activity of the wound fluid formed in the presence of NEI was diminished both under low-ionic conditions (P < .05; Figure 5A) and higher-ionic conditions (P < .05, except for C albicans; Figure 5B), but CGI had no effect (not shown). Semiquantitative Western analysis revealed that the concentration of protegrin was markedly reduced in the inhibitor chambers (35.3 ± 6.0 µg/mL) compared with control chambers (86.6 ± 16.8 µg/mL; P < .001) (n = 13-17). These data taken together would indicate that protegrin concentration and total antimicrobial activity of porcine wound fluid are directly correlated.
Because there was still an appreciable amount of ex vivo antimicrobial activity in the NEI-treated fluids, it is likely that unprocessed proprotegrin (Figure 1) or peptides processed from other unidentified pathways play a role in the antimicrobial activity of wound fluid. Other antimicrobial peptides identified in porcine wound fluid, including the prophenins,35 PR-39,36 and PMAPs,37 may also be processed to an active peptide by other enzymes or in their proform may contribute to the antimicrobial activity of wound fluid. The antimicrobial activity of NEI-inhibited wound fluids can be restored in vitro by the addition of neutrophil elastase or PG-1 Additional amounts of NEI added to collected wound fluids in vitro at 0.25 mM final concentration did not alter the antimicrobial activity of the fluids (Figure 6A; P > .5) (n = 6), indicating that NEI modified the antimicrobial activity of the fluid during its formation in vivo. If NEI acts predominantly by inhibiting the conversion of cathelicidin precursors into active protegrins, then adding excess elastase should restore this function. Figure 6B demonstrates that adding a final concentration of 100 µg/mL HNE to inhibited wound fluid in an RDA (10 mM NaP) fully restored the activity of inhibited fluid. It required 200 µg/mL of the less-specific porcine pancreatic elastase to only partially restore the antimicrobial activity (data not shown). Of note, neutrophil elastase alone had little antimicrobial activity (1.5 ± 0.5 RDU) (n = 3) in these permissive buffer conditions (data not shown).
The ability of only 100 µg/mL elastase (3.6 µM) to restore antimicrobial activity of wound fluid generated in the presence of 0.25 mM NEI indicated that the elastase-inhibitory activity of the fluid dissipated by the time of collection. To confirm the transient effect of NEI, we measured the residual inhibitory activity of NEI-treated wound fluid. Wound fluids from 3 separate NEI-treated chambers did not appreciably inhibit the elastolytic activity of 100, 250, or 500 µg/mL HNE (Alphasin Elastase Diffusion Plate, Elastin Products)(data not shown). Therefore, by the end of the 24-hour in vivo experiment, the NEI either diffused into the circulation, was bound, or was otherwise inactivated. The concentration of PG-1 required to restore the inhibited antimicrobial activity of NEI-treated wound fluid was determined by PG-1 titration in RDAs. Figure 6C (shaded bar) indicates that an average of 36 µg/mL PG-1 was necessary to fully restore the antimicrobial activity of NEI-treated fluids against E coli (n = 3). Similar results were obtained with S epidermidis (data not shown). The added PG-1 also brought the total concentration of protegrin to that in control wound fluids, as measured by Western analysis (Figure 6C, hatched bar; P > .5). The ability of PG-1 to fully restore the in vitro activity of NEI-inhibited wound fluid is further evidence that NEI acts predominantly by inhibiting protegrin activation. Supplementing wound chambers with PG-1 in vivo restores the microbicidal function of NEI-treated fluid To correct the protegrin reduction caused by the NEI, PG-1 was added to wound chambers concurrently with NEI and test bacteria. Two concentrations of PG-1 (20 and 200 µg/mL) completely cleared the chambers of S epidermidis CFUs (Figure 7A). The addition of PG-1 at the onset of the experiment likely killed the bacteria before colonization, proliferation, or both could occur. To approximate the more gradual time course of protegrin release, in the third experiment we added 1 µg/mL PG-1 4 hours after wound chamber preparation. This was sufficient to restore the in vivo antimicrobial activity to that of the solvent-only controls. The fluids were subjected to RDAs against S epidermidis (Figure 7B) and E coli, S aureus, P aeruginosa, and C albicans (not shown). The fluids from NEI-inhibited chambers to which 20 µg/mL or 1 µg/mL PG-1 was added in vivo did not differ in antimicrobial activity from the noninhibited control (P > .25), while the addition of 200 µg/mL PG-1 overcompensated for the NEI-inhibition (P < .003).
The roles of neutrophil elastase and protegrins in wound host defense This study explored the effects of a specific NEI on innate host defense in porcine skin wounds. The preceding experiments demonstrated that wound fluid generated in the presence of NEI is deficient in mature protegrin content, protegrin-associated antibacterial activity, and total antibacterial activity against a wide range of microbes. Moreover, NEI-treated wounds showed diminished clearance of fungi and Gram-positive and Gram-negative bacteria. We discerned no effects of 0.1-0.25 mM concentrations of NEI on neutrophil recruitment, phagocytic superoxide production, or degranulation of lysozyme. However, higher concentrations of NEI decreased neutrophil recruitment and thus could not be used for this study. CGI, an inhibitor of a neutrophil serine protease structurally similar to neutrophil elastase, had no detectable effects on antimicrobial activity in any of these assays. Taken together these experiments suggest that in the pig model, the NEI N-methoxysuccinyl-AAPV chloromethyl ketone impairs the clearance of skin bacteria from wounds, at least in part by blocking the elastase-mediated activation of antimicrobial protegrins. These findings also support the proposed role of antimicrobial peptides as effector molecules of host defense in mammals.The reduction of antimicrobial activity caused by NEI could be corrected by replacing the mature protegrin, thereby confirming the important contribution of elastase-processed protegrin to the antimicrobial activity of wound fluid. Initial tests showed that the in vitro antimicrobial activity of wound fluid could be restored to normal levels with an amount of protegrin equivalent to the measured difference between the protegrin concentrations in the control and inhibited chambers. In vivo, 1 µg/mL PG-1 added directly to the chambers 4 hours after bacterial inoculation was sufficient to compensate for the inhibition of local protegrin production. However, 1 µg/mL protegrin is less than the measured difference in approximately 50 µg/mL protegrin concentration between the control and inhibited chambers at 24 hours. Because protegrin is not yet detectable in wound fluid at 4 hours (Western analysis, data not shown), adding even minute amounts of protegrin earlier, when antimicrobial substance concentrations are still low, is likely to have a dramatic effect on the fluid's cumulative microbicidal activity. Finally, as expected from the proposed mechanism, the antimicrobial activity of wound fluid that had formed in the presence of NEI could be restored by adding excess neutrophil elastase in vitro. No elastase activity was detectable in cell-free wound fluid by
the chromogenic assay (data not shown) or with an elastin-based radial
diffusion assay (Alphasin Elastase Diffusion Plate, data not shown).
Our previous studies with the same neutrophil elastase-specific chromogenic substrate revealed that the enzymatic activity of 106 porcine PMNs was equivalent to 1 µg HNE, ie, similar
to that of human PMNs.15 Therefore, the porcine neutrophil
elastase concentration, which is derived from the average number of
neutrophils present in the wound fluid (approximately
1 × 107 PMN/mL), was approximately 1-10 µg/mL
(0.036-0.36 µM), assuming 10% to 100% degranulation and no
degradation. The in vivo concentration of NEI (0.1-0.25 mM) thus was at
least 270- to 700-fold greater than the amount necessary to inhibit the
activity of neutrophil elastase. The lack of elastase activity in the
cell-free wound fluid is consistent with the studies of other
biological fluids that contain plasma-derived elastase inhibitors. In
these fluids, elastase is only biologically active when bound to the
cell surface of neutrophils, where it is not inhibited by
In additional experiments, 200 µg PG-1 administered topically 24 hours after infection reduced bacterial CFUs by 10-fold at 48 hours in wounds inoculated with a highly infective strain of P aeruginosa (A.C., A.M.C., and T.G., unpublished data, September 2000). Indeed, Loury and colleagues39 have shown that topical administration of a protegrin derivative, IB-367, can significantly reduce microflora densities in experimentally induced hamster oral mucositis. Augmentation of the biological levels of antimicrobial peptides may become a useful strategy for the prevention and treatment of localized infections. Although neutrophil-specific protegrins are the most active antimicrobials in porcine wound fluid, the neutrophils also produce additional microbicidal peptides and proteins, some of which may be processed by other proteases. NEI might also affect the activity of additional serine and cysteine proteases that have not yet been identified. Extrapolation of the effects of neutrophil elastase inhibition to other peptides and mammalian species should therefore be made with caution. Although cathelicidins have also been found in human40-43 and murine neutrophils,44,45 neutrophils of other mammals,46 and neutrophils in several mammalian epithelia,47,48 mature cathelicidin peptides vary in their sequences as do their potential elastase cleavage sites. Two rabbit cathelicidins, p15A and p15B,49 apparently do not undergo proteolytic maturation, and they manifest microbicidal activity without it. Moreover, the human myeloid defensins are proteolytically processed to mature forms before storage in granules.50 Thus, further studies will be necessary to determine to what extent the findings in the pig model are applicable to other animals and humans. In the meantime, it may be prudent to monitor for clinical signs of impaired tissue microbicidal activity in experimental subjects who are receiving synthetic elastase inhibitors.
We thank Dr Edith M. Porter for critically reviewing this manuscript and Thomas Kang, Shawn McGill, Fernando Vinuela Jr, and John Robert for their technical contributions. We also express our gratitude to Dr Timothy Lawson, Director of the Division of Laboratory Animal Medicine, UCLA, Los Angeles, CA.
Submitted April 19, 2000; accepted September 8, 2000.
Supported by National Research Initiative Grant 98-35204-6594 (T.G. and J.S.) from the U.S. Department of Agriculture, Washington, DC; grant HL46809 (T.G.) and postdoctoral fellowship HL10181 (A.M.C.) from the National Institutes of Health, Bethesda, MD; a postdoctoral fellowship (A.M.C.) from the American Lung Association, New York, NY; and a postdoctoral fellowship (J.S.) from the Cystic Fibrosis Foundation, Bethesda, MD. J.S. is currently employed by the Biologicals Development Group, Pfizer Inc., Groton, CT.
A.M.C. and J.S. contributed equally to this manuscript.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Tomas Ganz, Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90095-1690; e-mail: tganz{at}ucla.edu.
1. Travis J. Structure, function, and control of neutrophil proteinases. Am J Med. 1988;84:37-42[Medline] [Order article via Infotrieve].
2.
Borregaard N, Cowland JB.
Granules of the human neutrophilic polymorphonuclear leukocyte.
Blood.
1997;89:3503-3521 3. Snider GL, Ciccolella DE, Morris SM, Stone PJ, Lucey EC. Putative role of neutrophil elastase in the pathogenesis of emphysema. Ann N Y Acad Sci. 1991;624:45-59[Medline] [Order article via Infotrieve]. 4. Doring G. The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med. 1994;150(suppl 6):S114-S117. 5. Shapiro SD. The pathogenesis of emphysema: the elastase:antielastase hypothesis 30 years later. Proc Assoc Am Physicians. 1995;107:346-352[Medline] [Order article via Infotrieve]. 6. Vender RL. Therapeutic potential of neutrophil-elastase inhibition in pulmonary disease. J Invest Med. 1996;44:531-539[Medline] [Order article via Infotrieve]. 7. Ganz T, Metcalf JA, Gallin JI, Boxer LA, Lehrer RI. Microbicidal/cytotoxic proteins of neutrophils are deficient in two disorders: Chediak-Higashi syndrome and "specific" granule deficiency. J Clin Invest. 1988;82:552-556. 8. Belaaouaj A, McCarthy R, Baumann M, et al. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med. 1998;4:615-618[CrossRef][Medline] [Order article via Infotrieve].
9.
Belaaouaj A, Kim KS, Shapiro SD.
Degradation of outer membrane protein A in Escherichia coli killing by neutrophil elastase.
Science.
2000;289:1185-1188
10.
MacIvor DM, Shapiro SD, Pham CT, Belaaouaj A, Abraham SN, Ley TJ.
Normal neutrophil function in cathepsin G-deficient mice.
Blood.
1999;94:4282-4293
11.
Thorne KJ, Oliver RC, Barrett AJ.
Lysis and killing of bacteria by lysosomal proteinases.
Infect Immun.
1976;14:555-563
12.
Zanetti M, Litteri L, Gennaro R, Horstmann H, Romeo D.
Bactenecins, defense polypeptides of bovine neutrophils, are generated from precursor molecules stored in the large granules.
J Cell Biol.
1990;111:1363-1371 13. Zanetti M, Litteri L, Griffiths G, Gennaro R, Romeo D. Stimulus-induced maturation of probactenecins, precursors of neutrophil antimicrobial polypeptides. J Immunol. 1991;146:4295-4300[Abstract]. 14. Scocchi M, Skerlavaj B, Romeo D, Gennaro R. Proteolytic cleavage by neutrophil elastase converts inactive storage proforms to antibacterial bactenecins. Eur J Biochem. 1992;209:589-595[Medline] [Order article via Infotrieve]. 15. Panyutich A, Shi J, Boutz PL, Zhao C, Ganz T. Porcine polymorphonuclear leukocytes generate extracellular microbicidal activity by elastase-mediated activation of secreted proprotegrins. Infect Immun. 1997;65:978-985[Abstract].
16.
Shi J, Ganz T.
The role of protegrins and other elastase-activated polypeptides in the bactericidal properties of porcine inflammatory fluids.
Infect Immun.
1998;66:3611-3617 17. Agerberth B, Lee JY, Bergman T, et al. Amino acid sequence of PR-39: isolation from pig intestine of a new member of the family of proline-arginine-rich antibacterial peptides. Eur J Biochem. 1991;202:849-854[Medline] [Order article via Infotrieve]. 18. Kokryakov VN, Harwig SS, Panyutich EA, et al. Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett. 1993;327:231-236[CrossRef][Medline] [Order article via Infotrieve]. 19. Storici P, Zanetti M. A cDNA derived from pig bone marrow cells predicts a sequence identical to the intestinal antibacterial peptide PR-39. Biochem Biophys Res Commun. 1993;196:1058-1065[CrossRef][Medline] [Order article via Infotrieve]. 20. Storici P, Zanetti M. A novel cDNA sequence encoding a pig leukocyte antimicrobial peptide with a cathelin-like pro-sequence. Biochem Biophys Res Commun. 1993;196:1363-1368[CrossRef][Medline] [Order article via Infotrieve]. 21. Zhao C, Liu L, Lehrer RI. Identification of a new member of the protegrin family by cDNA cloning. FEBS Lett. 1994;346:285-288[CrossRef][Medline] [Order article via Infotrieve]. 22. Harwig SS, Kokryakov VN, Swiderek KM, Aleshina GM, Zhao C, Lehrer RI. Prophenin-1, an exceptionally proline-rich antimicrobial peptide from porcine leukocytes. FEBS Lett. 1995;362:65-69[CrossRef][Medline] [Order article via Infotrieve]. 23. Strukelj B, Pungercar J, Kopitar G, et al. Molecular cloning and identification of a novel porcine cathelin-like antibacterial peptide precursor. Biol Chem Hoppe Seyler. 1995;376:507-510[Medline] [Order article via Infotrieve]. 24. Tossi A, Scocchi M, Zanetti M, Storici P, Gennaro R. PMAP-37, a novel antibacterial peptide from pig myeloid cells: cDNA cloning, chemical synthesis and activity. Eur J Biochem. 1995;228:941-946[Medline] [Order article via Infotrieve]. 25. Lee IH, Cho Y, Lehrer RI. Effects of pH and salinity on the antimicrobial properties of clavanins. Infect Immun. 1997;65:2898-2903[Abstract].
26.
Hancock RE, Mutharia LM, Chan L, Darveau RP, Speert DP, Pier GB.
Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains.
Infect Immun.
1983;42:170-177
27.
Gallo RL, Ono M, Povsic T, et al.
Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds.
Proc Natl Acad Sci U S A.
1994;91:11035-11039 28. Panyutich AV, Hiemstra PS, Van Wetering S, Ganz T. Human neutrophil defensins and serpins form complexes and inactivate each other. Am J Respir Cell Mol Biol. 1995;12:351-357[Abstract]. 29. Lehrer RI, Rosenman M, Harwig SS, Jackson R, Eisenhauer P. Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods. 1991;137:167-173[CrossRef][Medline] [Order article via Infotrieve]. 30. Osserman EF, Lawlor DP. Serum and urinary lysozyme (muramidase) in monocytic and monomyelocytic leukemia. J Exp Med. 1966;124:921-952[Abstract].
31.
Shi J, Ross CR, Leto TL, Blecha F.
PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox.
Proc Natl Acad Sci U S A.
1996;93:6014-6018
32.
Lomas DA, Stone SR, Llewellyn-Jones C, et al.
The control of neutrophil chemotaxis by inhibitors of cathepsin G and chymotrypsin.
J Biol Chem.
1995;270:23437-23443 33. Sibille Y, Merrill WW, Cooper JA Jr, Polomski L, Gee JB. Effects of a series of chloromethyl ketone protease inhibitors on superoxide release and the glutathione system in human polymorphonuclear leukocytes and alveolar macrophages. Am Rev Respir Dis. 1984;130:110-114[Medline] [Order article via Infotrieve]. 34. Baggiolini M, Bretz U, Dewald B, Feigenson ME. The polymorphonuclear leukocyte. Agents Actions. 1978;8:3-10[CrossRef][Medline] [Order article via Infotrieve]. 35. Harwig SS, Kokryakov VN, Swiderek KM, Aleshina GM, Zhao C, Lehrer RI. Prophenin-1, an exceptionally proline-rich antimicrobial peptide from porcine leukocytes. FEBS Lett. 1995;362:65-69. 36. Shi J, Ross CR, Chengappa MM, Blecha F. Identification of a proline-arginine-rich antibacterial peptide from neutrophils that is analogous to PR-39, an antibacterial peptide from the small intestine. J Leukoc Biol. 1994;56:807-811[Abstract]. 37. Tossi A, Scocchi M, Zanetti M, Storici P, Gennaro R. PMAP-37, a novel antibacterial peptide from pig myeloid cells: cDNA cloning, chemical synthesis and activity. Eur J Biochem. 1995;228:941-946.
38.
Owen CA, Campbell MA, Sannes PL, Boukedes SS, Campbell EJ.
Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases.
J Cell Biol.
1995;131:775-789 39. Loury D, Embree JR, Steinberg DA, Sonis ST, Fiddes JC. Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;87:544-551[CrossRef][Medline] [Order article via Infotrieve].
40.
Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH.
FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis.
Proc Natl Acad Sci U S A.
1995;92:195-199 41. Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, Wright SC. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun. 1995;63:1291-1297[Abstract]. 42. Cowland JB, Johnsen AH, Borregaard N. hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules. FEBS Lett. 1995;368:173-176[CrossRef][Medline] [Order article via Infotrieve]. 43. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Bioch. 1996;238:325-332[Medline] [Order article via Infotrieve]. 44. Moscinski LC, Hill B. Molecular cloning of a novel myeloid granule protein. J Cell Biochem. 1995;59:431-442[CrossRef][Medline] [Order article via Infotrieve].
45.
Gallo RL, Kim KJ, Bernfield M, et al.
Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse.
J Biol Chem.
1997;272:13088-13093 46. Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 1995;374:1-5[CrossRef][Medline] [Order article via Infotrieve].
47.
Frohm M, Agerberth B, Ahangari G, et al.
The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders.
J Biol Chem.
1997;272:15258-15263
48.
Bals R, Wang X, Wu Z, et al.
Human 49. Levy O, Weiss J, Ooi CE, Elsbach P. Structural characterization of BPI-modulating 15 kDa proteins from rabbit polymorphonuclear leukocytes: identification of a novel family of leukocyte proteins. Agents Actions. 1993;39 Spec No:C207-C210.
50.
Valore EV, Ganz T.
Posttranslational processing of defensins in immature human myeloid cells.
Blood.
1992;79:1538-1544
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  Q. C. K. Cheung, P. V. Turner, C. Song, D. Wu, H. Y. Cai, J. I. MacInnes, and J. Li Enhanced Resistance to Bacterial Infection in Protegrin-1 Transgenic Mice Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1812 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Di Nardo, M. H. Braff, K. R. Taylor, C. Na, R. D. Granstein, J. E. McInturff, S. Krutzik, R. L. Modlin, and R. L. Gallo Cathelicidin Antimicrobial Peptides Block Dendritic Cell TLR4 Activation and Allergic Contact Sensitization J. Immunol., February 1, 2007; 178(3): 1829 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. de Haar, P. S. Hiemstra, M. T. J. M. van Steenbergen, V. Everts, and W. Beertsen Role of Polymorphonuclear Leukocyte-Derived Serine Proteinases in Defense against Actinobacillus actinomycetemcomitans Infect. Immun., September 1, 2006; 74(9): 5284 - 5291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Braff, M. Zaiou, J. Fierer, V. Nizet, and R. L. Gallo Keratinocyte Production of Cathelicidin Provides Direct Activity against Bacterial Skin Pathogens Infect. Immun., October 1, 2005; 73(10): 6771 - 6781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-G. Sahl, U. Pag, S. Bonness, S. Wagner, N. Antcheva, and A. Tossi Mammalian defensins: structures and mechanism of antibiotic activity J. Leukoc. Biol., April 1, 2005; 77(4): 466 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Borregaard, K. Theilgaard-Monch, J. B. Cowland, M. Stahle, and O. E. Sorensen Neutrophils and keratinocytes in innate immunity--cooperative actions to provide antimicrobial defense at the right time and place J. Leukoc. Biol., April 1, 2005; 77(4): 439 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. A. Lee, T. Ohtake, M. Zaiou, M. Murakami, J. A. Rudisill, K. H. Lin, and R. L. Gallo From The Cover: Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection PNAS, March 8, 2005; 102(10): 3750 - 3755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sieprawska-Lupa, P. Mydel, K. Krawczyk, K. Wojcik, M. Puklo, B. Lupa, P. Suder, J. Silberring, M. Reed, J. Pohl, et al. Degradation of Human Antimicrobial Peptide LL-37 by Staphylococcus aureus-Derived Proteinases Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4673 - 4679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Levy Antimicrobial proteins and peptides: anti-infective molecules of mammalian leukocytes J. Leukoc. Biol., November 1, 2004; 76(5): 909 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Murakami, B. Lopez-Garcia, M. Braff, R. A. Dorschner, and R. L. Gallo Postsecretory Processing Generates Multiple Cathelicidins for Enhanced Topical Antimicrobial Defense J. Immunol., March 1, 2004; 172(5): 3070 - 3077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Rosenberger, R. L. Gallo, and B. B. Finlay Interplay between antibacterial effectors: A macrophage antimicrobial peptide impairs intracellular Salmonella replication PNAS, February 24, 2004; 101(8): 2422 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mullick, M. Elias, P. Harakidas, A. Marcil, M. Whiteway, B. Ge, T. J. Hudson, A. W. Caron, L. Bourget, S. Picard, et al. Gene Expression in HL60 Granulocytoids and Human Polymorphonuclear Leukocytes Exposed to Candida albicans{dagger} Infect. Immun., January 1, 2004; 72(1): 414 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ganz Antimicrobial polypeptides J. Leukoc. Biol., January 1, 2004; 75(1): 34 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zanetti Cathelicidins, multifunctional peptides of the innate immunity J. Leukoc. Biol., January 1, 2004; 75(1): 39 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. E. Sorensen, L. Gram, A. H. Johnsen, E. Andersson, S. Bangsboll, G. S. Tjabringa, P. S. Hiemstra, J. Malm, A. Egesten, and N. Borregaard Processing of Seminal Plasma hCAP-18 to ALL-38 by Gastricsin: A NOVEL MECHANISM OF GENERATING ANTIMICROBIAL PEPTIDES IN VAGINA J. Biol. Chem., August 1, 2003; 278(31): 28540 - 28546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ganz The Role of Antimicrobial Peptides in Innate Immunity Integr. Comp. Biol., April 1, 2003; 43(2): 300 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Bajaj-Elliott Trypsin and host defence: a new role for an old enzyme Gut, February 1, 2003; 52(2): 166 - 167. [Full Text] [PDF]
|
|
|
|
|
|
D. G. Perregaux, K. Bhavsar, L. Contillo, J. Shi, and C. A. Gabel Antimicrobial Peptides Initiate IL-1{beta} Posttranslational Processing: A Novel Role Beyond Innate Immunity J. Immunol., March 15, 2002; 168(6): 3024 - 3032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Sawai, A. J. Waring, W. R. Kearney, P. B. McCray Jr, W. R. Forsyth, R. I. Lehrer, and B. F. Tack Impact of single-residue mutations on the structure and function of ovispirin/novispirin antimicrobial peptides Protein Eng. Des. Sel., March 1, 2002; 15(3): 225 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. LEE and G. P. DOWNEY Leukocyte Elastase . Physiological Functions and Role in Acute Lung Injury Am. J. Respir. Crit. Care Med., September 1, 2001; 164(5): 896 - 904. [Full Text] [PDF]
|
|
|
|
 |
|
 O. E. Sorensen, P. Follin, A. H. Johnsen, J. Calafat, G. S. Tjabringa, P. S. Hiemstra, and N. Borregaard Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3 Blood, June 15, 2001; 97(12): 3951 - 3959. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
, 10 mM NaP) and higher-ionic conditions (
, 10 mM NaP/100 mM
NaCl) (n = 4). Antimicrobial activity is expressed as RDUs. Error
bars represent SEM.
-1-antiprotease and other plasma-derived inhibitors but remains
accessible to low molecular weight inhibitors.
-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung.
J Clin Invest.
1998;102:874-880